M
Michael Hutchinson
Researcher at University College Dublin
Publications - 397
Citations - 27664
Michael Hutchinson is an academic researcher from University College Dublin. The author has contributed to research in topics: Multiple sclerosis & Cervical dystonia. The author has an hindex of 59, co-authored 389 publications receiving 25352 citations. Previous affiliations of Michael Hutchinson include New York University & Trinity College, Dublin.
Papers
More filters
Journal ArticleDOI
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more
TL;DR: These revisions simplify the McDonald Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and more uniform and widespread use.
Journal ArticleDOI
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
Chris H. Polman,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,David Miller,J. Theodore Phillips,Fred D. Lublin,Gavin Giovannoni,A Wajgt,Martin Toal,F Lynn,Michael Panzara,Alfred Sandrock +12 more
TL;DR: Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.
Journal ArticleDOI
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
Christian Confavreux,Michael Hutchinson,Martine Hours,Cortinovis-Tourniaire P,Thibault Moreau +4 more
TL;DR: This study studied 254 women with multiple sclerosis during 269 pregnancies in 12 European countries to determine the rate of relapse per trimester and the score on the Kurtzke Expanded Disability Status Scale.
Journal ArticleDOI
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox,David Miller,J. Theodore Phillips,Michael Hutchinson,Eva Havrdova,Mariko Kita,Minhua Yang,Kartik Raghupathi,Mark Novas,Marianne T. Sweetser,Vissia Viglietta,Katherine Dawson,Christian Sindic +12 more
TL;DR: In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo.
Journal ArticleDOI
Differential diagnosis of suspected multiple sclerosis: a consensus approach
David Miller,Brian G. Weinshenker,Massimo Filippi,Brenda Banwell,Jeffrey A. Cohen,Mark S. Freedman,SL Galetta,Michael Hutchinson,Richard T. Johnson,Ludwig Kappos,Jun Ichi Kira,Fred D. Lublin,Henry F. McFarland,Xavier Montalban,Hillel Panitch,J. R. Richert,Stephen C. Reingold,Chris H. Polman,Chris H. Polman +18 more
TL;DR: This paper developed guidelines for MS differential diagnosis, focusing on exclusion of potential MS mimics, diagnosis of common initial isolated clinical syndromes, and differentiating between MS and non-MS idiopathic inflammatory demyelinating diseases.